🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

AFAR is pleased to announce the election of Alex Colville of age1 to its Board of Directors. Please join AFAR in welcoming him to this position, and learn more about his leadership experience here: afar.org/news/colvillee…

Thanks to Eric Sun from Brunet Lab James Zou lab for presenting work on transcriptomic mapping and understanding the aging brain, at age1 / Gordian Biotechnology joint happy hour!

New story from me this morn. Max Hodak and Science are out to spur a brain research boom. bloomberg.com/news/articles/…

🚀🚀🚀

Where is the longevity field in its growth trajectory? There's now a club at Harvard devoted to it!!

Last Monday I hosted an age1 dinner with over 3 dozen folks working in policy, economics, biotech and tech. Common discussion topic? > how do you actually get in touch with regulators who have decision making power (and more importantly, willingness to do it)

The age of Neural Engineering is here... and Max Hodak's Science Corp is on the frontier: ‣ Curing blindness ‣ Merging mind & machine with BCIs ‣ Today, revealing a new kind of neural probe ‣ And exploring consciousness itself on Episode 65 of S3.

Where are we on the path to extending #healthspan? Excited to be working with Satvik Dasariraju to bring together this incredible lineup kat age1 NFX Hevolution Foundation Omar Abudayyeh Jonathan Gootenberg Novartis Harvard University Joan Mannick Dec 8, 12:45-2pm Harvard Business School

It was a lot of fun to speak today at the aging workshop panel during Harvard Business School Heath Care Club’s conference! One key takeaway I have from the discussions is how do we develop transformative technologies for aging on a realistic timeline? This circles back to a larger

I love meeting interesting ppl — Satvik Dasariraju and I have been teaming up to host small group age1 dinners in Cambridge and hope to expand our invite list (and locations!) in 2025! If you want to join us, fill out form linked below :)

docs.google.com/forms/d/1uU77p…

We’re excited to select Faun1083 as our first development candidate. Discovered through our proprietary Convergence™ drug discovery platform, Faun1083 is a potential first-in-class therapeutic targeting heart failure with preserved ejection fraction. 🧬 businesswire.com/news/home/2025…